- Vienna 2018
- Athens 2019
- ESCRS Player
- On Demand
- ESCRS iLearn
- ESCRS YO's
Session Title: Glaucoma
Session Date/Time: Monday 07/10/2013 | 17:00-18:34
Paper Time: 17:10
Venue: Elicium 2 (First Floor)
First Author: : F.Aptel FRANCE
Co Author(s): : P. Denis J. Rouland J. Nordmann Y. Lachkar J. Renard E.
We aimed to evaluate the efficacy and safety of the Ultrasonic Circular Cyclo Coagulation (UC3) procedure.
Nine French glaucoma centers.
Prospective non-comparative interventional clinical study. Forty-two eyes of 42 patients with primary open-angle glaucoma (POAG), intraocular pressure (IOP) > 21 mmHg, an average of 1.65 failed previous surgeries and an average of 3.2 hypotensive medications were insonified with a therapy probe comprising 6 piezoelectric transducers. The 6 transducers were activated, 18 patients (group 1) were treated with a 4 seconds exposure time for each shot and 29 patients (group 2) with a 6 seconds exposure time. Complete ophthalmic examinations were performed before the procedure, and at 1 day, 1 week, 1, 2, 3, 6 and 12 months after. Primary outcomes were surgical success (defined as IOP reduction from baseline ? 20% and IOP > 5mmHg) at the last follow-up visit, and vision-threatening complications. Secondary outcomes were mean IOP at each follow-up visits compared to baseline, medication use, complications, and re-interventions.
IOP was significantly reduced in both groups (p<0.05), from a mean preoperative value of 29.4 ± 4.7 mmHg in group 1 and 29.1 ± 7.8 mmHg in group 2 to a mean value of 17.0 ± 4.2 mmHg in group 1 and 17.9 ± 4.1 mmHg in group 2 at last follow-up. Success (IOP reduction >20%) was achieved in 10 of 18 (60%) eyes of the group 1 and in 21 of 29 (72%) eyes of the group 2 at last follow-up. Four patients were ret-treated. No major intra- or post-operative complications occurred.
Ultrasonic Circular Cyclo Coagulation seems to be an effective and well-tolerated method to reduce intraocular pressure in patients with POAG.
... receives consulting fees, retainer, or contract payments from a company producing, developing or supplying the product or procedure presented, ... travel has been funded, fully or partially, by a company producing, developing or supplying the product or procedure presented, ... research is funded, fully or partially, by a company producing, developing or supplying the product or procedure presented
Please wait while information is loading.